as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹573.7
Change
-13.15 (-2.24%)
Open
₹584.95
Prev. Close
₹586.85
Day High
₹587.2
Day Low
₹572.0
Volume Analysis
Traded
202,605
Delivered
108,179
Delivery %
53.39%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (2)
- •Low return on equity (9.52%)
- •Promoter holding is falling
Opportunities (1)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹598.46 | ₹592.83 | ₹583.26 | ₹577.63 | ₹568.06 | ₹562.43 | ₹552.86 |
| Fibonacci | ₹592.83 | ₹587.02 | ₹583.44 | ₹577.63 | ₹571.82 | ₹568.24 | ₹562.43 |
| Camarilla | ₹577.88 | ₹576.49 | ₹575.09 | ₹577.63 | ₹572.31 | ₹570.91 | ₹569.52 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-18.85%
1 Week
-4.36%
1 Month
-3.89%
3 Months
-20.14%
6 Months
-21.17%
1 Year
-20.79%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹285.77
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
9.42%
Net margin 7.13% × asset turnover 0.73x × equity multiplier 1.81x
Company Overview
Sector
Chemicals
Market Cap
₹9,340 Cr
P/E (TTM)
26.0
ROE
9.52%
Book Value
₹208.0
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.
TopFund Analysis
Jubilant Ingrevia Limited lands in the middle of the pack on TopFund's composite fundamentals check within the Chemicals sector, at 61/100. The strongest factor is Financial Strength (100/100), while Momentum (20/100) is the weakest area to weigh before deciding. Notably: Low return on equity (9.52%); promoter holding is falling. FII holding has been rising.
TopFund Score — Fundamentals Quality
61/100 — AverageData confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has been maintaining a healthy dividend payout of 34.4%
- +Company's working capital requirements have reduced from 29.4 days to 22.0 days
- −Stock is trading at 2.83 times its book value
- −Company has a low return on equity of 8.49% over last 3 years.
- −Promoter holding has decreased over last 3 years: -6.25%
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Management of the Company will be participating in Kotak Midcap Conference 2026 scheduled on 26th & 27th November, 2026
JAEL executed SSPA to acquire 40% of Zettaone, with option to raise stake to 51% in FY28.
Newspaper advertisement for dispatch of postal ballot notice
Transcript of the Investors'' Conference Call for un-audited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, held on …
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,020 | 966 | 1,074 | 1,024 | 1,045 | 1,057 | 1,051 | 1,038 | 1,121 | 1,051 | 1,179 | 1,300 | 1,394 |
| Expenses + | 902 | 871 | 983 | 915 | 921 | 918 | 905 | 896 | 985 | 924 | 1,016 | 1,101 | 1,182 |
| Operating Profit | 118 | 96 | 91 | 110 | 124 | 138 | 147 | 142 | 135 | 126 | 163 | 199 | 212 |
| OPM % | 12.0% | 10.0% | 8.0% | 11.0% | 12.0% | 13.0% | 14.0% | 14.0% | 12.0% | 12.0% | 14.0% | 15.0% | 15.0% |
| Other Income + | 9 | 9 | 10 | 10 | 10 | 9 | 8 | 11 | 11 | -4 | 9 | 10 | 9 |
| Interest | 13 | 15 | 14 | 14 | 15 | 12 | 14 | 13 | 12 | 12 | 12 | 17 | 22 |
| Depreciation | 34 | 34 | 36 | 39 | 40 | 40 | 39 | 41 | 41 | 45 | 48 | 51 | 51 |
| Profit before tax | 80 | 55 | 51 | 66 | 80 | 96 | 102 | 100 | 93 | 65 | 112 | 141 | 148 |
| Tax % | 28.0% | 30.0% | 43.0% | 26.0% | 26.0% | 27.0% | 27.0% | 25.0% | 25.0% | 28.0% | 23.0% | 25.0% | 25.0% |
| Net Profit + | 57 | 39 | 29 | 49 | 59 | 69 | 74 | 75 | 69 | 47 | 86 | 106 | 111 |
| EPS in Rs | 4 | 2 | 2 | 3 | 4 | 4 | 5 | 5 | 4 | 3 | 5 | 7 | 7 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | -22 | -17 | -6 | -5 | 2 | 9 | -2 | 1 | 7 | -1 | 12 | 25 | 24 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 0 | 684 | 4,949 | 4,773 | 4,136 | 4,178 | 4,388 | 4,924 |
| Expenses + | 0 | 567 | 4,108 | 4,224 | 3,708 | 3,658 | 3,820 | 4,224 |
| Operating Profit | 0 | 117 | 841 | 549 | 427 | 519 | 568 | 700 |
| OPM % | — | 17.0% | 17.0% | 11.0% | 10.0% | 12.0% | 13.0% | 14.0% |
| Other Income + | 0 | -10 | 22 | 32 | 29 | 38 | 27 | 25 |
| Interest | 0 | 7 | 31 | 22 | 53 | 56 | 49 | 64 |
| Depreciation | 0 | 22 | 123 | 122 | 136 | 158 | 175 | 195 |
| Profit before tax | 0 | 77 | 709 | 437 | 268 | 344 | 370 | 466 |
| Tax % | 0.0% | 30.0% | 33.0% | 30.0% | 32.0% | 27.0% | 25.0% | — |
| Net Profit + | 0 | 54 | 477 | 308 | 183 | 251 | 278 | 351 |
| EPS in Rs | -3 | 3 | 30 | 19 | 11 | 16 | 17 | 22 |
| Dividend Payout % | 0.0% | 10.0% | 17.0% | 26.0% | 43.0% | 31.0% | 28.0% | — |
| Sales growth | — | — | 623 | -4 | -13 | 1 | 5 | 15 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|
| Reserves | 0 | 1,907 | 2,417 | 2,650 | 2,722 | 2,911 | 3,110 | 3,301 |
| Borrowings + | 0 | 556 | 238 | 407 | 740 | 764 | 792 | 895 |
| Other Liabilities + | 0 | 888 | 1,111 | 1,176 | 1,241 | 1,324 | 1,551 | 1,787 |
| Total Liabilities | 0 | 3,366 | 3,782 | 4,249 | 4,719 | 5,015 | 5,470 | 5,999 |
| Fixed Assets + | 0 | 1,805 | 1,798 | 1,846 | 2,539 | 2,581 | 3,183 | 3,157 |
| CWIP | 0 | 65 | 174 | 525 | 331 | 525 | 154 | 281 |
| Investments | 0 | 50 | 6 | 8 | 15 | 37 | 33 | 37 |
| Other Assets + | 0 | 1,446 | 1,804 | 1,870 | 1,834 | 1,872 | 2,099 | 2,524 |
| Total Assets | 0 | 3,366 | 3,782 | 4,249 | 4,719 | 5,015 | 5,470 | 5,999 |
| Equity Capital | 0 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 0 | 112 | 453 | 462 | 430 | 508 | 524 |
| Cash from Investing Activity + | 0 | 33 | -71 | -469 | -568 | -389 | -250 |
| Cash from Financing Activity + | 0 | -72 | -418 | 42 | 144 | -129 | -155 |
| Net Cash Flow | 0 | 73 | -36 | 35 | 6 | -9 | 119 |
| Free Cash Flow | 0 | 85 | 225 | -16 | -136 | 156 | 235 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 0 | 106 | 69 | 98 | 111 | 113 | 111 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Others | 0.82% | 0.81% | 0.81% | 0.77% | 0.74% | 0.73% | 0.72% | 0.82% | 0.8% | 0.98% | 0.98% | 0.96% |
| Public | 30.17% | 27.53% | 27.1% | 25.09% | 24.9% | 24.76% | 25.3% | 24.94% | 23.8% | 22.53% | 22.3% | 21.69% |
| Promoters | 51.47% | 51.47% | 51.47% | 51.47% | 51.47% | 51.47% | 45.22% | 45.22% | 45.22% | 45.22% | 45.22% | 45.22% |
| Government | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% |
| FII | 6.35% | 6.58% | 6.55% | 7.22% | 6.89% | 7.12% | 6.96% | 5.96% | 6.15% | 6.49% | 6.49% | 6.93% |
| DII | 11.17% | 13.6% | 14.07% | 15.47% | 15.99% | 15.91% | 21.81% | 23.04% | 24.0% | 24.76% | 24.98% | 25.18% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Chemicals — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Jubilant Ingrevia Limited (this stock) | 9,340 | 26.0 | 2.82 | 9.52% |
| Sudarshan Chemical Inds L | 9,219 | 61.2 | 2.52 | 0.54% |
| Neogen Chemicals Limited | 8,526 | 211.0 | 5.41 | 3.58% |
| Alkyl Amines Chem. Ltd | 8,235 | 43.4 | 15.33 | 41.4% |
| Galaxy Surfactants Ltd | 7,852 | 18.8 | 2.64 | 10.9% |
| Pcbl Chemical Limited | 11,117 | 40.1 | 2.75 | 5.56% |
| Clean Science & Tech Ltd | 7,524 | 32.3 | 4.5 | 15.3% |
Which Mutual Funds Hold Jubilant Ingrevia Limited?
Frequently Asked Questions about Jubilant Ingrevia Limited
Jubilant Ingrevia Limited (JUBLINGREA) closed at ₹573.7 on NSE on 19 November 2026, down 13.15 (2.24%) from the previous close.
Jubilant Ingrevia Limited trades on the NSE (National Stock Exchange of India) under the symbol JUBLINGREA.
Jubilant Ingrevia Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 26.0.
Jubilant Ingrevia Limited has a dividend yield of 0.85%.
Jubilant Ingrevia Limited's 52-week high is ₹795.0 and its 52-week low is ₹535.0.
Jubilant Ingrevia Limited has a market capitalisation of ₹9,340 crore.
Jubilant Ingrevia Limited has a TopFund Quality Score of 61/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Jubilant Ingrevia Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.